Li Renzhe, Hu Chao, Liu Chang, Lyness Thomas, Li Wenyuan, Cai Chen-Yan, Crossley Eric, Kanda Yuzuru, Merchant Rohan R, Matsuura Bryan S, Williams Noelle S, Qin Tian
Department of Biochemistry, The University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, Texas 75390, United States.
Novartis Biomedical Research, Cambridge, Massachusetts 02139, United States.
J Am Chem Soc. 2025 Sep 12. doi: 10.1021/jacs.5c10954.
A general and modular strategy has been developed for the synthesis of -SF azetidines, a new class of scaffolds with potential utility in medicinal chemistry. This transformation leverages bench-stable and scalable SF-transfer reagents to generate the SF radical, which engages azabicyclo[1.1.0]butanes bearing ketone, ester, alkyl, or aryl substituents in strain-release difunctionalization reactions. The method proceeds under mild reaction conditions, features broad functional group tolerance, and offers operational simplicity. The resulting -SF azetidines demonstrate high aqueous stability and increased lipophilicity, positioning them as a novel class of potential bioisosteres in medicinal chemistry.
已开发出一种通用且模块化的策略来合成含硫氮杂环丁烷,这是一类在药物化学中具有潜在应用价值的新型骨架。这种转化利用易于操作且可扩展的硫转移试剂来生成硫自由基,该自由基在应变释放双官能化反应中与带有酮、酯、烷基或芳基取代基的氮杂双环[1.1.0]丁烷发生反应。该方法在温和的反应条件下进行,具有广泛的官能团耐受性,且操作简便。所得的含硫氮杂环丁烷表现出高水稳定性和增加的亲脂性,使其成为药物化学中一类新型的潜在生物电子等排体。